DeatonC,FroelicherES,WuLA,HoC,ShishaniK,JaarsmaT.,,2011,The global burden of cardiovascular disease,Eur J Cardiovasc Nurs,10,5,13
LowWY,LeeYK,SamyAL,,2015,Non communicable diseases in the Asia pacific region: prevalence, risk factors and community based prevention,Int J Occup Med Environ Health,28,20,6
Libby P.,McGraw-Hill Medical,,2008,The pathogenesis, prevention and treatment of atherosclerosis,Harrison's principle of internal medicine. 17ed,,1501,9
FrancoM,CooperRS,BilalU,FusterV,,2011,Challenges and opportunities for cardiovascular disease prevention,Am J Med,124,95,102
Nutr J,,2014,,,13,17,
LorenzatiB,ZuccoC,MiglitettaS,LambertiF,BrunoG,,2010,Oral hypoglycemic drugs: pathophysiological basis of their mechanism of action,Pharmaceuticals,3,3005,20
LokeYK,KwokCS,SinghS. Comparative,d1309 TzoulakiI,MolokhiaM,CurcinV,LittleMP,MillettCJ,NgA,,2011,cardiovascular effects of thiazolidinediones: systemic review and meta- analysis of observational studies,BMJ,342,,
Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral anti diabetic drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
InbarajSD,JosephineIG,,2014,Comparative study of lipids and glycemic effect of pioglitazone, rosiglitazone with glibenclamide in patients with type 2 diabetes and dyslipidemia,Global J Pharmacol,8,107,13
PanickerGK,KarnadDR,SalviV,KothariS.,,2012,Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirement of new drug,J Assoc Physicians India,60,56,61
GenoveseS,De BerardisG,NicolucciA,MannucciE,EvangelistaV,TotaniL,,2013,Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes,Adv Ther,30,190,202
StoneNJ,BilekS,RosenbaumS.,,2005,Recent national cholesterol education program adult panel III update: adjustment and opitions,Am J Cardiol,96,53,9
Yki-JarvinenH.,Thiazolidinediones,,2004,,N Eng J Med,351,18,
WildingJP.,,2014,The importance of weight management in type 2 diabetes mellitus,Int J Clin Pract,68,682,91
KodamaN,TaharaN,TaharaT,HondaA,NittaY,MizoguchiM,,2013,Effect of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus,J Clin Endocrinol Metab,98,4438,45
,2016,Pleiotropic actions of peroxisome proliferator activated receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives,Int J Mol Sci,17,999,
ShokouhP,JoharimoghadamA,RoohafzaH,SadeghiM,GolabchiA,BoshtamM,,2013,Effect of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in non diabetic patients (EPICAMP study) a double blind randomized controlled trials,PPAR Res,,358074,
WinklerK,KonradT,FullertS,FriedrichI,DestaniR,BaumstarkMW,,2003,Pioglitazone reduces atherogenic dense LDL particle in non diabetic patients with arterial hypertension,Diabetes Care,26,2588,94
Campia U. MatuskeyLA,PanzaJA,,2006,Peroxisome proliferator activated receptor-? activation with pioglitazone improves endothelium dependent dilation in non diabetic patients with major cardiovascular risk factors,Circulation,113,867,75
Leonhardt W, Pfutzner A, Muller J, Pietzsch J, Forst T, Karagiannis E, et al. Effect of pioglitazone and/ or simvastatin on low density lipoprotein sub fractions in non diabetic-patients with high cardiovascular risk: a sub- analysis of piostat study. Atherosclerosis 2008; 201: 155-62.
ChristophM,HeroldJ,Berg-HolldackA,RauwolfT,ZiemseenT,SchmeisserA,,2015,Effects of PPAR? agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non diabetic patients: double centered randomized controlled VH-IVUS pilot trial,Heart Vessels,30,286,95
ForstT,WilhelmB,PfutznerA,LehmannU,SchaperF,WeberM,,2008,Investigation of the vascular and Pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk,Diabetes Vasc Dis Res,5,298,303
BalakumarP,MahadevanN.,,2010,Interplay between statins and PPARs in improving cardiovascular outcomes: a double edged sword?,Br J Pharmacol,165,373,9
Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator activated receptor agonists: potential treatment of atherogenicdyslipidemia and non alcoholic fatty liver disease.
Expert Opin Pharmacother 2014; 15: 493-503.